… GM-CSF axis in COVID-19 … COVID-19 lung injury, the marked elevation in GM-CSF levels
as part of the cytokine storm during the onset of COVID-19 pneumonia suggests that GM-CSF …

… increased production of GM-CSF in patients with COVID-19 represents a physiological …
We, along with others 1,72 , suggest that in patients with COVID-19, dysregulated GM-CSF …

… more likely to use G-CSF than GM-CSF in persons with COVID-19-related ARDS. This may
… G-CSF-induced influx of granulocytes in the lung, an effect not seen with GM-CSF. However, …

… effect of GM-CSF inhibition in COVID-19 and support further … Granulocyte–macrophage
colony-stimulating factor (GM-CSF… COVID-19 pneumonia by inhibition of the GM-CSF pathway. …

… GM-CSF levels in both ICU and non-ICU treated COVID-19 … of GM-CSF + Th1 cells in patients
with COVID-19 requiring ICU … Additionally, a population of IL-17A and GM-CSF expressing …

… -stimulation in COVID-19 and … GM-CSF in the treatment of COVID-19. Lenzilumab was
offered through a compassionate single-use IND to patients with severe and critical COVID-19 …

… strategy to prevent mortality due to COVID-19. In this respect, … in the treatment of severe
COVID-19 and is still being tested in … being tested as potential treatment targets in COVID-19. 6 …

… to neutralize GM-CSF in the treatment of COVID-19. … patients with severe and critical
COVID-19 pneumonia. Based on … -induced GM-CSF depletion prevents CRS in COVID-19 and …

… of GM-CSF and myeloid cells in COVID-19 pathogenesis [10… Anti-GM-CSF namilumab
demonstrated a reduction in CRP in … of anti-GM-CSF monotherapy in COVID-19 may be linked to …

… GM-CSF,4, 5 and there is accumulating evidence for targeting GM-CSF in patients with severe
COVID-19… Bronchoalveolar lavage fluid analysis from patients with severe COVID-19 has …